New Classifications for Myelodysplastic Syndromes (MDS)
Posted: January 17, 2017 Filed under: CRUSH!!MDS, Uncategorized | Tags: cancer, hematology, Leukemia, MDS, Myelodysplastic Syndrome, Oncology, Research, Weill Cornell Medical College Comments Off on New Classifications for Myelodysplastic Syndromes (MDS)Dr. Ellen Ritchie recently participated in an OncLive discussion on the latest modifications to the World Health Organization (WHO) classification of Myelodysplastic Syndromes (MDS). WHO classification is the standard diagnostic system utilized by medical institutions worldwide, including here at Weill Cornell Medicine. Recent advances in our understanding of the biological course of MDS have warranted revision to its WHO classification, which was last updated in 2008. In particular, mutational and cytogenetic analyses have to led to refinement of diagnostic terms for MDS. These modifications include a distinction between single versus multilineage dysplasia and elimination of the term “cytopenia.”
The OncLive discussion centered on implications of the new classification on the prognosis and treatment of MDS. While the WHO classification is just one of many factors to consider when evaluating the prognosis of the disorder, the panelists agree that the new modifications will make it easier to determine an appropriate course of treatment for their patients. To learn more, click here or watch the video below.
Weill Cornell Leukemia Program Abstracts @ ASH 2016
Posted: December 5, 2016 Filed under: Leukemia News, Uncategorized | Tags: acute lymphocytic leukemia, Acute Myeloid Leukemia, ALL, AML, Blood Disorders, bone marrow, cancer, cancer treatment, chemotherapy, CML, hematology, Leukemia, Leukemia News, MDS, Oncology, Research Comments Off on Weill Cornell Leukemia Program Abstracts @ ASH 2016December is an exciting month here at the Leukemia Program, as each year, our doctors and researchers are invited to attend and present their work at the annual meeting of the American Society of Hematology (ASH). This important meeting provides the opportunity to network with thousands of hematology specialists from all over the world.
This year, the 58th ASH Annual Meeting & Exposition is being held December 3-6 in San Diego, California. We are very proud to play an integral role in research that is changing the way leukemia is diagnosed, tracked and treated. The below abstracts are being presented in oral or poster sessions by the Leukemia Program’s physicians, researchers, and collaborators.
AML
#438. BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation
#599. Changes of the Mutational Landscape in Relapsed Acute Myeloid Leukemia
#1077. CD97 Is a Critical Regulator of Acute Myeloid Leukemia Stem Cell Function
#1680. Genetic Determinants of Response to Guadecitabine (SGI-110) in AML
ALL
CML
MPN
MDS
Cancer Care: The Next Generation
Posted: September 20, 2016 Filed under: Clinical Trials, Leukemia News, Patient Education, Uncategorized | Tags: Blood Disorders, cancer treatment, Gail Roboz, hematology, Leukemia, Leukemia Treatment, MDS, Myelodysplastic Syndrome, New York Presbyterian, Weill Cornell, Weill Cornell Leukemia Program Comments Off on Cancer Care: The Next GenerationDr. Gail Roboz on ABC talks about “taking a chance on something new.” [go]
Dr. Pinkal Desai Discusses a Clinical Trial of SGI-110 for People with MDS/MPN and CMMoL
Posted: April 13, 2016 Filed under: Clinical Trials, CRUSH!!MDS, Uncategorized | Tags: Blood Disorders, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, hematology, Juvenile Myelomonocytic Leukemia, Leukemia, MDS, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, New York Presbyterian, Weill Cornell Comments Off on Dr. Pinkal Desai Discusses a Clinical Trial of SGI-110 for People with MDS/MPN and CMMoLThis clinical study is aimed at men and women with a diagnosis of: Chronic Neutrophilic Leukemia (CNL), Chronic Myelomonocytic Leuekmia (CMML), atypical Chronic Myeloid Leukemia (aCML), Juvenile Myelomonocytic Leukemia (JMML), and Myelodysplastic & Myeloproliferative Neoplasm Unclassifiable (MDS/MPN-U). Click here to learn more or see if you are eligible to participate.
Dr. Desai – Treatment for Intermediate & High Risk MDS
Posted: March 10, 2016 Filed under: CRUSH!!MDS, Patient Education, Physician Presentations, Uncategorized | Tags: Blood Disorders, hematology, Leukemia Treatment, MDS, MDS Treatment, Myelodysplastic Syndrome, Pinkal Desai, Weill Cornell Comments Off on Dr. Desai – Treatment for Intermediate & High Risk MDSDr. Desai discusses approved treatments for intermediate and high risk MDS. For more information visit crushmds.org.
Are You a Patient Taking Vidaza or Dacogen?
Posted: February 8, 2016 Filed under: Clinical Trials, CRUSH!!MDS, Laboratory Research, Patient Education, Uncategorized | Tags: Blood Disorders, dacogen, Gail Roboz, Leukemia Treatment, MDS, Myelodysplastic Syndrome, vidaza, Weill Cornell, Weill Cornell Leukemia Program Comments Off on Are You a Patient Taking Vidaza or Dacogen?Seeking Research Volunteers
Predicting Response To Your Myelodysplastic Syndrome (MDS) Treatment
Azacitidine (Vidaza®) and decitabine (Dacogen®) are FDA-approved drugs for the treatment of MDS. While these drugs help many patients with MDS, sometimes patients who initially respond to these drugs eventually lose their response. Why? Why do the drugs stop working? MDS-CRC investigators are trying to answer this question. Through CRUSH!!MDS, we are recruiting patients who have not responded or lost their initial response to azacitidine or decitabine. Patients will be able to have blood drawn at the time of a routine visit to their local doctor and we will arrange for the blood to be delivered to Weill Cornell Medical College, at no cost to the patient. At Weill Cornell, the blood will be analyzed in the laboratory of Dr. Joseph Scandura, M.D.
For more information about the study and the CRUSH!!MDS initiative, please visit our website.
Dr. Gail Roboz featured in Parade Magazine
Posted: April 8, 2013 Filed under: Accolades, Leukemia News | Tags: Blood Disorders, Gail Roboz, MDS, Myelodysplastic Syndrome, New York Presbyterian, Weill Cornell Comments Off on Dr. Gail Roboz featured in Parade Magazine Dr. Gail Roboz was interviewed and photographed alongside Good Morning America anchor and her bone marrow transplant doctor on March 31, 2013. To read the full article, click here.
Dr. Gail Roboz appears on ABC’s 20/20
Posted: March 5, 2013 Filed under: Accolades, Uncategorized | Tags: Blood Disorders, Gail Roboz, Gail Roboz MD, MDS, Myelodysplastic Syndrome, New York Presbyterian, Weill Cornell Comments Off on Dr. Gail Roboz appears on ABC’s 20/20 Leukemia Program Director, Gail Roboz, M.D. interviewed on ABC’s 20/20. To watch the interview, click here. To read the related article, click here.
Dr. Gail Roboz appears on Good Morning America
Posted: February 22, 2013 Filed under: Accolades, Uncategorized | Tags: Gail Roboz, Gail Roboz MD, MDS, Myelodysplastic Syndrome Comments Off on Dr. Gail Roboz appears on Good Morning America To view the interview, click here.
Dr. Gail Roboz Makes 6th Appearance on Good Morning America
Posted: January 14, 2013 Filed under: Accolades, Physician Presentations, Uncategorized | Tags: Blood Disorders, Gail Roboz, Gail Roboz MD, MDS, Myelodysplastic Syndrome, New York Presbyterian, Weill Cornell Comments Off on Dr. Gail Roboz Makes 6th Appearance on Good Morning AmericaTo view the interview, click here.